S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Biden and GOP reach debt-ceiling deal. Now Congress must approve it to prevent calamitous default
Unofficial results in Turkey’s presidential runoff split in early counting
15 A.I. Trading Opportunities a Day (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Biden and GOP reach debt-ceiling deal. Now Congress must approve it to prevent calamitous default
Unofficial results in Turkey’s presidential runoff split in early counting
15 A.I. Trading Opportunities a Day (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Biden and GOP reach debt-ceiling deal. Now Congress must approve it to prevent calamitous default
Unofficial results in Turkey’s presidential runoff split in early counting
15 A.I. Trading Opportunities a Day (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Biden and GOP reach debt-ceiling deal. Now Congress must approve it to prevent calamitous default
Unofficial results in Turkey’s presidential runoff split in early counting
15 A.I. Trading Opportunities a Day (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
NASDAQ:FBIO

Fortress Biotech (FBIO) Stock Forecast, Price & News

$0.55
+0.06 (+12.27%)
(As of 05/26/2023 ET)
Compare
Today's Range
$0.49
$0.56
50-Day Range
$0.49
$0.82
52-Week Range
$0.48
$1.33
Volume
1.26 million shs
Average Volume
866,200 shs
Market Capitalization
$73.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Fortress Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
901.8% Upside
$5.50 Price Target
Short Interest
Healthy
0.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.03mentions of Fortress Biotech in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.81) to ($0.44) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

651st out of 1,012 stocks

Pharmaceutical Preparations Industry

326th out of 495 stocks


FBIO stock logo

About Fortress Biotech (NASDAQ:FBIO) Stock

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Receive FBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter.

FBIO Stock News Headlines

Surprising "Twist" Hands Biden Landslide Re-election?
This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.
Fortress Biotech (NASDAQ:FBIO) PT Lowered to $5.00
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Mustang Bio Announces Reverse Stock Split
See More Headlines
Receive FBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter.

FBIO Company Calendar

Last Earnings
3/30/2023
Today
5/28/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:FBIO
CUSIP
21976U10
Employees
173
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.50
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+901.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-86,570,000.00
Net Margins
-143.74%
Pretax Margin
-341.08%

Debt

Sales & Book Value

Annual Sales
$75.74 million
Book Value
$0.15 per share

Miscellaneous

Free Float
98,998,000
Market Cap
$73.74 million
Optionable
Optionable
Beta
1.99

Key Executives

  • Lindsay Allan Rosenwald
    Chairman, President & Chief Executive Officer
  • David Jin
    CFO & Head-Corporate Development
  • George C. Avgerinos
    Senior Vice President-Biologics Operations
  • Michael Sean Weiss
    Executive Vice Chairman
  • Brian Achenbach
    Vice President-Finance & Controller













FBIO Stock - Frequently Asked Questions

Should I buy or sell Fortress Biotech stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FBIO shares.
View FBIO analyst ratings
or view top-rated stocks.

What is Fortress Biotech's stock price forecast for 2023?

5 Wall Street research analysts have issued twelve-month target prices for Fortress Biotech's stock. Their FBIO share price forecasts range from $5.00 to $6.00. On average, they expect the company's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 901.8% from the stock's current price.
View analysts price targets for FBIO
or view top-rated stocks among Wall Street analysts.

How have FBIO shares performed in 2023?

Fortress Biotech's stock was trading at $0.6550 at the start of the year. Since then, FBIO stock has decreased by 16.2% and is now trading at $0.5490.
View the best growth stocks for 2023 here
.

Are investors shorting Fortress Biotech?

Fortress Biotech saw a increase in short interest in May. As of May 15th, there was short interest totaling 702,900 shares, an increase of 6.8% from the April 30th total of 658,400 shares. Based on an average daily trading volume, of 673,500 shares, the short-interest ratio is presently 1.0 days. Currently, 0.8% of the company's shares are sold short.
View Fortress Biotech's Short Interest
.

When is Fortress Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our FBIO earnings forecast
.

How were Fortress Biotech's earnings last quarter?

Fortress Biotech, Inc. (NASDAQ:FBIO) posted its quarterly earnings data on Thursday, March, 30th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.08. The biopharmaceutical company earned $16.40 million during the quarter, compared to the consensus estimate of $25.20 million. Fortress Biotech had a negative trailing twelve-month return on equity of 115.85% and a negative net margin of 143.74%.

What other stocks do shareholders of Fortress Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Novavax (NVAX), Advanced Micro Devices (AMD), OPKO Health (OPK), TG Therapeutics (TGTX), Vaxart (VXRT), NVIDIA (NVDA), Pfizer (PFE) and Dynavax Technologies (DVAX).

What is Fortress Biotech's stock symbol?

Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."

Who are Fortress Biotech's major shareholders?

Fortress Biotech's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Perkins Capital Management Inc. (1.09%), Shikiar Asset Management Inc. (0.90%), Acadian Asset Management LLC (0.78%), Geode Capital Management LLC (0.54%), B. Riley Wealth Advisors Inc. (0.14%) and HighTower Advisors LLC (0.07%). Insiders that own company stock include Eric K Rowinsky, Lindsay A Md Rosenwald, Malcolm Hoenlein and Robyn Hunter.
View institutional ownership trends
.

How do I buy shares of Fortress Biotech?

Shares of FBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fortress Biotech's stock price today?

One share of FBIO stock can currently be purchased for approximately $0.55.

How much money does Fortress Biotech make?

Fortress Biotech (NASDAQ:FBIO) has a market capitalization of $73.74 million and generates $75.74 million in revenue each year. The biopharmaceutical company earns $-86,570,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis.

How many employees does Fortress Biotech have?

The company employs 173 workers across the globe.

How can I contact Fortress Biotech?

Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The official website for the company is www.fortressbiotech.com. The biopharmaceutical company can be reached via phone at (781) 652-4500, via email at ir@fortressbiotech.com, or via fax at 781-652-4545.

This page (NASDAQ:FBIO) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -